Literature DB >> 21273615

Prognostic value of the human antigen R (HuR) in human breast cancer: high level predicts a favourable prognosis.

Zhu Yuan1, Andrew J Sanders, Lin Ye, Yu Wang, Wen G Jiang.   

Abstract

BACKGROUND: The role of human antigen R (HuR) and its prognostic value in breast cancer is currently only partially understood. This study aimed to determine the levels of expression of HuR in breast cancer and assess its prognostic value.
MATERIALS AND METHODS: HuR expression levels were assessed in a cohort of human breast cancer specimens and cell lines using both quantitative and qualitative analysis along with immunohistochemical techniques and the results were compared to the patient details.
RESULTS: Immunohistochemical staining revealed a weak HuR staining pattern in breast tumour sections compared to the intense epithelial staining of the normal breast tissues. The levels of HuR transcripts were lower in the more advanced TNM4 and TNM3, poor outcome NPI-2 (Nottingham Prognostic Index) and NPI-3 and node-positive tumours compared with the early stage TNM2 and TNM1, NPI-1, and node-negative tumours, although these values did not reach statistical significance. The patients with metastasis, those who died of breast cancer and those with bone metastasis had significantly decreased levels of HuR transcripts, (p=0.031, p=0.018 or p=0.038 respectively) compared to the disease-free patients. The patients with poor prognosis, including those with metastasis and those who died of breast cancer, had a significantly lower level of HuR transcripts compared to the disease-free patients (p=0.021). High levels of HuR correlated with longer overall survival, although the values did not reach statistical significance (p=0.06).
CONCLUSION: While no significant association of the levels of HuR expression with pathological status of breast cancer is reported, HuR may represent a prognostic factor in human breast cancer, as patients expressing high levels of HuR have a favourable prognosis, and the prognostic role of HuR for breast cancer metastasis, particularly bone metastasis is supported.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21273615

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  15 in total

1.  Insights from the HuR-interacting transcriptome: ncRNAs, ubiquitin pathways, and patterns of secondary structure dependent RNA interactions.

Authors:  Georges St Laurent; Dmitry Shtokalo; Mohammad Heydarian; Andrey Palyanov; Dmitry Babiy; Jianhua Zhou; Ajit Kumar; Silvio Urcuqui-Inchima
Journal:  Mol Genet Genomics       Date:  2012-10-04       Impact factor: 3.291

2.  Elevated Hu-Antigen Receptor (HuR) Expression is Associated with Tumor Aggressiveness and Poor Prognosis but not with COX-2 Expression in Invasive Breast Carcinoma Patients.

Authors:  Constantinos Giaginis; Anastasia Sampani; Iolly Kotta-Loizou; Ioanna Giannopoulou; Eugene Danas; Ekaterini Politi; Gerasimos Tsourouflis; Gregorios Kouraklis; Efstratios Patsouris; Antonios Keramopoulos; Lydia Nakopoulou; Stamatios Theocharis
Journal:  Pathol Oncol Res       Date:  2017-08-14       Impact factor: 3.201

Review 3.  Clinical significance of HuR expression in human malignancy.

Authors:  Ioly Kotta-Loizou; Constantinos Giaginis; Stamatios Theocharis
Journal:  Med Oncol       Date:  2014-08-13       Impact factor: 3.064

Review 4.  Regulation of the mRNA half-life in breast cancer.

Authors:  Paola Griseri; Gilles Pagès
Journal:  World J Clin Oncol       Date:  2014-08-10

5.  BOPC1 Enantiomers Preparation and HuR Interaction Study. From Molecular Modeling to a Curious DEEP-STD NMR Application.

Authors:  Serena Della Volpe; Roberta Listro; Michela Parafioriti; Marcello Di Giacomo; Daniela Rossi; Francesca Alessandra Ambrosio; Giosuè Costa; Stefano Alcaro; Francesco Ortuso; Anna K H Hirsch; Francesca Vasile; Simona Collina
Journal:  ACS Med Chem Lett       Date:  2020-01-28       Impact factor: 4.345

6.  Human antigen R as a predictive marker for response to gemcitabine-based chemotherapy in advanced cisplatin-resistant urothelial cancer.

Authors:  Yasuyoshi Miyata; Kensuke Mitsunari; Asai Akihiro; Shin-Ichi Watanabe; Tomohiro Matsuo; Kojiro Ohba; Hideki Sakai
Journal:  Oncol Lett       Date:  2016-12-12       Impact factor: 2.967

7.  Cytoplasmic expression of the ELAV-like protein HuR as a potential prognostic marker in esophageal squamous cell carcinoma.

Authors:  Cong Zhang; Guoliang Xue; Jingwang Bi; Ming Geng; Huili Chu; Yaping Guan; Jun Wang; Baocheng Wang
Journal:  Tumour Biol       Date:  2013-07-20

8.  Cytoplasmic HuR expression correlates with P-gp, HER-2 positivity, and poor outcome in breast cancer.

Authors:  Zhongpeng Zhu; Baocheng Wang; Jingwang Bi; Cong Zhang; Yan Guo; Huili Chu; Xiuju Liang; Chen Zhong; Jun Wang
Journal:  Tumour Biol       Date:  2013-04-19

9.  The RNA-binding protein HuR is a novel target of Pirh2 E3 ubiquitin ligase.

Authors:  Alexandra Daks; Alexey Petukhov; Olga Fedorova; Oleg Shuvalov; Alena Kizenko; Elizaveta Tananykina; Elena Vasileva; Oleg Semenov; Andrew Bottrill; Nickolai Barlev
Journal:  Cell Death Dis       Date:  2021-06-05       Impact factor: 8.469

Review 10.  Multiple functions of the RNA-binding protein HuR in cancer progression, treatment responses and prognosis.

Authors:  Jun Wang; Yan Guo; Huili Chu; Yaping Guan; Jingwang Bi; Baocheng Wang
Journal:  Int J Mol Sci       Date:  2013-05-10       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.